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Recruitment of p300/CBP in p53-Dependent
Signal Pathways
Maria Laura Avantaggiati,*# Vasily Ogryzko,² The acetylation of histones is thought to be involved in
destabilization and restructuring of nucleosomes, whichKevin Gardner,* Antonio Giordano,§
is likely a crucial event for accessibility of transcriptionArthur S. Levine,³ and Kathleen Kelly*‖
factors to DNA templates. These studies thus suggested*Laboratory of Pathology
that p300/CBP participates to the transcription processNational Cancer Institute
by scaffolding different classes of transcriptional regula-²Laboratory of Molecular Growth Regulation
tors on specific chromatin domains.³Section on DNA Replication, Repair, and
A role for p300/CBP in control of cellular growth hasMutagenesis
been proposed on the basis of the functional behaviorNational Institute of Child Health and Human
of adenovirus E1a and SV40 Tag proteins, which lose theDevelopment
ability tobind top300/CBP (Moran, 1993; Avantaggiati etNational Institutes of Health
al., 1996; Eckner et al., 1996a). Such mutants are defec-Bethesda, Maryland 20892
tive in the induction of cellular DNA synthesis and, in§Sbarro Institute for Cancer Research and
several instances, of transformation. In addition, we andMolecular Medicine
others have shown that the activity(s) of p300/CBP isThomas Jefferson University
required for the activation of muscle-specific genes andPhiladelphia, Pennsylvania 19107
for cell cycle arrest during differentiation of muscle cells
(Eckner et al., 1996b; Puri et al., 1997). Moreover, muta-Summary
tions or translocations of the p300, or of the CBP, genes
have been described in human tumors (Borrow et al.,
The products of the p53 and CBP/p300 genes have 1996; Muraoka et al., 1996). p300 mutations in colorectal
been individually implicated in control of cell growth carcinomas are somatic and coupled to deletion of the
and regulation of transcription. p53 is known to act as second allele of the gene, suggesting that p300 isconse-
a positive and negative regulator of gene expression. quently inactivated. On the basis of this evidence, p300/
Here we show that p53, in both wild-type and mutant CBP is envisioned as a negative regulator of cell growth.
conformation, forms a specific protein complex with The p53 tumor suppressor is also a common target
p300. However, in its wild-type but not mutant confor- for genetic alteration in human cancers (reviewed in
mation, p53 inhibits a promoter containing the DNA- Haffner and Oren, 1995; Ko and Prives, 1996; Levine,
binding sequences for the transcription factor AP1, in 1997). Such genetic lesions disrupt the tumor sup-
a p300-dependent manner. p300 stimulates the tran- pressive function of the protein and, in specific in-
scriptional activity of p53 on p53-regulated promoters, stances, actively contribute to uncontrolled proliferation
and it enhances the responsiveness to a physiological (Jenkins et al., 1985; Hinds et al., 1989). Wild-type p53
upstream modulator of p53 function, ionizing radia- limits cellular proliferation by inducing either a transient
tion. A dominant negative form of p300 prevents tran- G1 arrest or apoptosis, depending on the cellular con-
scriptional activation by p53, and it counteracts p53- text. A molecular explanation for the growth-arrest re-
sponse mediated by p53 relies on its ability to act asmediated G1 arrest and apoptosis. The data implicate
a sequence-specific DNA-binding transcription factor.p300 as an important component of p53-signaling,
Various downstream target genes of p53 have beenthus providing new insight into the mechanisms of
identified, such as p21/WAF, MDM2, GADD45, cyclin Gcellular proliferation.
and bax, whose expression products function as regula-
tors of diverse aspects of cell growth (reviewed by KoIntroduction
and Prives, 1996; Levine, 1997). Several p53 mutations
found in human tumors occur in the region encodingp300 and CBP are highly homologous nuclear proteins
the DNA-binding domain and, consequently, mutant p53originally identified for their ability to interact with ade-
proteins lose transactivating activity. Therefore, at leastnovirus E1a proteins and with the transcription factor
one unifying feature that might account for the differentCREB, respectively. Both members of this family are
biological effects of mutant p53 consists of their alteredregulators of transcription and interact with a variety of
ability to modulate gene expression.cellular as well as viral proteins. Among these are SV40
In addition to activating transcription, p53 acts as alarge T antigen (Tag), transcription factors such as
negative regulator of genes whose promoters do notMyoD, c-Jun, JunB, c-Fos, Myb and YY1, nuclear recep-
contain p53-binding sites. Although most studies dem-tors, and basal components of the transcriptional appa-
onstrating p53-mediated transrepression have utilized
ratus (Janknecht and Hunter, 1996a, and references
transient expression assays, endogenously repressed
therein). In addition, p300/CBP possesses histone ace-
genes have recently been identified (Miyashita et al.,
tyltransferase activity resulting either from intrinsic ac- 1994; Murphy et al., 1996). The mechanism by which p53
tivity and/or from an associated protein, P/CAF (Bannis- exerts this inhibition is likely to be through its physical
ter et al., 1996; Ogryzko et al., 1996; Yang et al., 1996). interaction with either basal components of the tran-
scriptional machinery,such as TBP, or otherunidentified
transcription factors (Ko and Prives, 1996, and refer-‖To whom correspondence should be addressed.
ences therein). Significantly, the transrepression func-#Present address: Department of Microbiology, School of Medicine,
State University of New York, Buffalo, New York 14214. tion of p53 appears to be especially important for the
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Figure 1. p300/CBP Is Detected in DNA-
Bound Complexes together with p53
Binding activity of cellular nuclear extracts
derived from a rat embryo-fibroblast cell line,
REF52, and from the embryo kidney carci-
noma cell line, 293, (lanes 3±9, panels [A] and
[B], respectively), to an oligonucleotide car-
rying three adjacent copies of the p53-DNA-
binding site. In both panels, lanes 3 show the
binding pattern to the DNA obtained with the
extracts alone: a major DNA±protein complex
is indicated by the lowerarrows (marked p53-
p300). For the other lanes, the antibodies indi-
cated at the top of the panels were added to
the binding reactions. Incubation with either
the anti-53 antibody pAb421 (lanes 7), or the
anti-p300 polyclonal (lanes 4) generates a
band with lower mobility (marked Ab/protein,
upper arrow). In lanes 5 and 6, nuclear cell
extracts were incubated with a controlpreim-
mune serum and with an anti-CBP specific
monoclonal antibody (UBI), respectively. In
lanes 8, theanti-p53 and anti-p300 antibodies
were added together. Lanes 9 contain the
competition with a 10-fold molar excess of
unlabeled oligonucleotide. In lanes 2, the anti-
p300 polyclonal antibody was incubated with
the probe in the absence of the cell extracts.
apoptotic activity of the protein (Levine, 1997), as sug- phoretic mobility gel assays (EMSA) were performed
using an oligonucleotide containing three copies of thegested by the fact that proteins inhibiting p53-mediated
apoptosis, such as Bcl2 and the adenovirus E1B, pre- p53 consensus site derived from the promoter of the
p21/WAF1 gene. Nuclear extracts of REF52 and 293vent trancriptional repression without affecting tran-
scriptional activation by p53 (Shen and Shenk, 1994). cells (Figures 1A and 1B, respectively) gave rise to a
major band (lanes 3, both panels) that was competedMutated forms of p53 found in human cancer cells have
been shown to lose their transrepression function and by an excess of cold oligonucleotide and supershifted
by the anti-p53 antibody pAb421 (lanes 7 and 9, respec-can even acquire a stimulatory activity on the same
promoters, PCNA and MDR1, for example, that are re- tively). The mobility of this p53-containing complex was
significantly retarded by a polyclonal antibody directedpressed by wild-type p53 (Chen et al., 1992; Deb et al.,
1992). against both CBP and p300, but not by a preimmune
rabbit antiserum (lanes 4 and 5) nor by a monoclonalBecause p300/CBP and p53 are both implicated in
regulation of transcription and control of cell growth, antibody directed against CBP (lanes 6). Incubation of
cell extracts with the anti-p53 and anti-p300 antibodieswe sought to investigate the possibility of a functional
cross-talk between these proteins. In this study, we together resulted in a further diffuse supershifted band
(lanes 8). Hence p300/CBP is contained in a specificshow that p53 and p300 form a specific protein complex.
We demonstrate that p53-mediated inhibition of AP1- DNA-bound protein complex together with p53.
To confirm the ability of p300 to bind to p53, immuno-regulated enhancers and transcriptional activation of
promoters containing a p53 consensus site are both precipitations followed by Western blots were per-
formed. CV1 cells were transfected with a plasmid en-p300 dependent. Furthermore, a temperature-sensitive
p53 mutant (p53 Val135) continues to bind to p300 but, coding wild-type p53, CMVp53, and 48 hr later, cell
extracts derived from the transfected cells were sub-in contrast with the wild-type, stimulates AP1 transcrip-
tion. A dominant negative form of p300 inhibits p53- jected to immunoprecipitation with either a monoclonal
anti-p53 antibody, pAb421, or with the polyclonal anti-dependent transcription, and it counteracts radiation-
induced G1-arrest and apoptosis. Our results implicate p300 antiserum (Figure 2A, lanes 2 and 3, respectively).
Western blot analysis of these precipitates revealed thep300 as an important effector of several of the known
activities of p53. Given that p300 appears to be a target presence of a discrete fraction of p300 associated with
p53. In contrast, we could not detect CBP in associationfor both transcriptional repression and activation by p53,
we propose that the modulation of p300 activities at with p53. Whether this is due to a relative insensitivity
of the immunoprecipitation assays or to an exquisitetargeted promoters plays a role in the execution of p53-
dependent signal pathways. specificity of p53 for p300, is unclear.
We next investigated whether p53 requires its native
conformation to bind p300 by utilizing a temperature-Results
sensitive p53 mutant that substitutes valine for alanine
in position 135 (p53 Val135) (Michalovitz et al., 1990). Anp300 Interacts with p53
We investigated whether p53 and p300 can be detected embryonic fibroblast cell line derived from homozygous
null mice for the p53 gene (MEF) was transfected within a specific protein complex bound to the DNA. Electro-
p300/CBP-p53 Cross-Talk
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Figure 2. p300 Interacts with Wild-Type and
Mutant p53
(A) Cell extracts derived from CV1 cells
transfected with 10 mg of the p53-expressing
vector (CMVp53) were immunoprecipitated
with a control, null, IgG2A monoclonal anti-
body (lane 1), with the anti-p53 antibody
pAb421, (lane 2), or with the anti-p300 poly-
clonal antiserum (lane 3). After electropho-
resis and electroblotting, the membranes
containing immobilized immuno-complexes
were subjected to Western blot by using a
mixture of three p300 monoclonal antibodies
(RW128, RW105, RW109, UBI).
(B) Mouse embryo fibroblasts derived from
double p53 null gene (MEFp532/2) mice were
transfected with a CMV-driven plasmid en-
coding the temperature-sensitive p53 mu-
tant, p53Val135. Cells were incubated at the
permissive (32.58C, lanes 1 and 4) or nonper-
missive (39.58C, lanes 2 and 3) temperature
for 36 hr after transfection. Cell extracts de-
rived from the transfected cells were mixed
with similarly prepared extracts of mock-
transfected cells, immunoprecipitated with
either anti-p53 (lanes 1 and 2) or anti-p300
antibodies (lanes 3 and 4), and assayed for the presence of p300 in a Western blot, as described in (A). Lane 5 contains the immunoprecipitation
with the control, null, IgG2A antibody from the mock-transfected cells incubated at 32.58C.
(C) 100 mg of total extracts derived from the transfection in (B) were probed in a Western blot with the pAb421 to monitor the expression of wild-
type and mutant p53. Lanes 1 and 2 contain extracts from cells transfected with p53Val135 and incubated at the permissive or nonpermissive
temperature, respectively. Cell extracts derived from the nontransfected cells were loaded in lane 3. In all panels, the position of p300 and
p53 is marked by the arrows.
a vector encoding p53 Val135. Cell extracts were immu- p300 Is an Important Component of
p53-Dependent Transcriptionnoprecipitated with the anti-p53 antibody pAb421,
which recognizes both wild-type and mutant conforma- Based on the results shown above, and because p300
and p53 are both transcriptional regulators, we investi-tion, or with the anti-p300 antiserum (Figure 2B). To
monitor the expression of p53, an anti-p53-specific gated the effects of p300 on p53-dependent transcrip-
tion. The p300-expressing vector (CMVp300), alone orWestern blot was performed (Figure 2C). p300 was de-
tected in the anti-p53 immunoprecipitations derived in combination with a vector encoding p53 (CMVp53),
was cotransfected into MEF(p532/2) cells together withfrom cells incubated at the permissive (32.58C) and, to a
lesser extent, in thecells incubated at the nonpermissive a reporter containing a synthetic p53 binding site placed
upstream of the luciferase gene (PG13). The expression(39.58C) temperature (Figure 2B, lanes 1 and 2, respec-
tively), indicating that both wild-type and mutant p53 of p300 in MEF cells had no significant effect on the
levels of activation of the reporter in the absence ofare capable of interacting with p300. Moreover, in keep-
ing with the results shown above, it appears that com- cotransfected wild-type p53 (Figure 4A). Transfection of
the p53-expressing vector produced a marked stimula-plex formation between p300 and p53 is conserved
among different cell lines, suggesting the involvement tion of transcription, as expected. A significant stimula-
tion of the reporter above the levels observed with p53of these proteins in common function(s).
To identify the region of p300 that interacts with p53, alone was specifically induced by coexpression of full-
length p300. This stimulatory effect was not observeda series of p300 deletion mutants translated in vitro in
presence of 35S-cysteine were individually mixed with following exogenous expression of p300(D242±1737),
which lacks the p53 binding site. Therefore, the tran-cellular extracts containing endogenous p53 and immu-
noprecipitated with the anti-p53 antibody. The nature of scriptional activity of p53 is enhanced by p300.
The structural and functional properties of p300 arethese mutations is illustrated in Figure 3A. The region of
p300 extending from residues 1514 to 1922, p300(1514± consistent with the possibility that it acts as a transcrip-
tional adapter molecule that scaffolds transcription fac-1922), exhibited the highest binding activity for p53,
while neither a large internal deletion, p300(D242±1737), tors and basal components of the transcriptional ma-
chinery at targeted promoters. Disruption of the activitynor a p300 fragment containing only the amino-terminal
portion were capable of generating detectable interac- of p300 is thus expected to perturb transcriptional acti-
vation. Thus, the effects of the p300(1514±1922), whichtions (Figure 3B). These results were confirmed with a
second approach by using baculovirus-expressed p300 contains the minimal regions of p53 binding but not
other regulatory domains, were examined. We antici-proteins (data not shown).
Therefore, p53 binds to the C-terminal domain of p300 pated that this molecule might prevent the activation of
p53-regulated promoters by interfering with complexbetween amino acids 1514±1737, which encompasses
a region upstream and partially included in the third formation between endogenous p53 and p300. The ex-
pression of p300(1514±1922) inhibited the activationcysteine/histidine-rich domain.
Cell
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Figure 3. Regions of Interaction between p53 and p300
(A) Schematic diagram of the four p300 deletion used. Thick and
thin lines indicate included and excluded sequences, respectively.
The bromodomain (marked as Br by shaded box) and the three
cysteine/histidine-rich domains (C/H1, C/H2 and C/H3, striped
boxes) are indicated.
(B) The various p300 proteins were translated in vitro by using a
coupled transcription/translation reticulocyte-based system (Pro-
mega) in the presence of 35S-cysteine. Five microliters of each trans-
lation reaction was run on an 8% gel and the efficiency of translation
was monitored by autoradiography of the gel (not shown). The quan-
tities of translated proteins were normalized accordingly to expose
p53 to similar amounts of p300. Translated proteins were mixed
with 1 mg of cell extracts derived from Cos7 cells, preincubated on Figure 4. p300 Enhances p53-Directed Transcription
ice for 309, and immunoprecipitated with a control IgG2A or with
A luciferasereporter containing 13copies of a synthetic p53 consen-
p53 specific antibodies as indicated at the top of the panels.
sus site derived from the promoter of p21/WAF1 (PG13) was used
in these assays.
(A) MEF cells (p532/2) were cotransfected with 0.5 mg of the p53
reporter and 1.5 mg of the plasmids expressing full-length p300driven by p53 in cells lacking endogenous p53 (Figure
(CMVp300); or p300(1514±1922), containing the regions required for4A). Moreover a dose-dependent inhibition of the p53
the interaction with p53; or p300(D242±1737), which does not bind
reporter was observed in CV1 cells that constitutively to p53. The left and the right of the panel (open bars and striped
produce p53 (Figure 4B). Significantly, this inhibition was bars, respectively) show the levels of luciferase activity obtained in
MEF cells cotransfected with the various p300 fragments in thereversed by increasing concentrations of the plasmid
absence or presence of 1.5 mg of cotransfected p53, respectively.encoding full-length p300, suggesting that p300(1514±
(B) p300(1514±1922) inhibits p53-dependent transcription in a dose-1922) likely acts by competing with endogenous p300
dependent manner. CV1 cells were transfected with 0.5 mg of the
for p53 interaction. No differences in the expression p53 reporter alone (open bar) or with increasing concentrations of
levels and in the subcellular localization of p53 were p300(1514±1922) (0.5, 1.5, 3, and 6 mg, light striped bars), with 6 mg
observed as a consequence of overexpression of the of the control plasmid CMV0 (dark striped bar). To explore whether
the inhibition of p53-mediated transcription produced by p300p300(1514±1922) (see Figure 7). Thus, p300 appears to
(1514±1922) can be restored by full-length p300, maximally inhibitorybe an important component of p53-directed tran-
concentrations (6 mg) of the CMVp53 plasmid were cotransfectedscription.
together with increasing amounts (1, 4, and 8 mg, black bars) of
Recent evidence indicates that p53 is crucially in- CMVp300. Cells were transfected with lipofectamine. The total DNA
volved in a signal pathway that is induced by ionizing content was equalized in each sample with the backbone plasmid,
radiation (IR) and, through the activation of p53-respon- CMV0, in (A), and with the pUC19 plasmid in (B). Samples were
assayed for luciferase activity 36±48 hr after transfection, and equalsive genes, leads to arrest of the cell cycle at the G1/S
amount of cell lysates were used for detection. The highest valueand G2/M checkpoints (Ko and Prives, 1996; Levine,
was arbitrarily set as 100 and all other consequently adjusted.1997; and references therein). To establish whether p300
p300/CBP-p53 Cross-Talk
1179
is involved in IR responsiveness, we examined the ef-
fects of p300 expression on p53-dependent transcrip-
tion following IR treatment of the human breast carci-
noma cells, MCF7. The transcriptional activity of p53
was enhanced by signals initiated by IR, as indicated
by a time-dependent increase in the activity of the re-
porter in cells transfected with p53 alone (Figure 5A).
This could be related to changes in theexpression levels
of p53 induced by irradiation (see Figure 5B) and/or
to qualitative modifications that enhance the intrinsic
activity of p53. Similarly, p300-mediated stimulation of
p53 transcription was significantly higher in irradiated
cells. This suggests that p53 and p300 act in concert
to modulate intracellular signals activated by DNA
damage.
Wild-Type and Mutant p53 Perturb
p300-Mediated Activation of the TRE
Wild-type p53 is known to inhibit the expression of sev-
eral genes whose promoters do not contain a p53-bind-
ing site. This inhibition has been attributed to the interac-
tion and functional sequestration of several components
of the transcriptional apparatus (Ko and Prives, 1996).
Thus, we sought to examine the effects of p53 on a Figure 5. Effects of p300 on p53-Dependent Transcription during
promoter containing the DNA consensus site for the IR Treatment of MCF7 Cells
transcription factorAP1 (TRE), whose activation is p300- (A) Human breast carcinoma cells (MCF7) were transfected with 0.5
dependent (Arias et al., 1994). Transfection of the plas- mg of the p53 reporter and 1 mg of the vector encoding full-length
p300 (CMV-p300) alone or in combination with 1 mg of the p53-mid encoding the temperature-sensitive mutant p53
expressing plasmid (CMV-p53), by using a calcium phosphate(p53 Val135) resulted in a strong inhibition of the TRE
method (Pharmacia). The levels of DNA wereequalized in allsamplesreporter after incubation of the cells at the permissive
with thebackbone vector, CMV0.Eighteen to 24 hr after transfection,temperature (Figure 6A). Incubation at the restrictive
cells were exposed to a total of 6.3 Gy, 137Cs source delivering
temperature that induces the mutant conformation pro- gamma-rays at a dose rate of 3.46 Gy/min. Equal amounts of cell
duced a small but reproducible stimulation of the TRE. lysates were assayed for luciferase activity at the indicated times
thereafter (0, 4, 9 hr, respectively).AP1-dependent transcription was enhanced upon ex-
(B) Total cellular extracts derived from nonirradiated (0 hr) or irradi-pression of full-length p300 and, to a lesser extent, of
ated cells (4 hr) and transfected as indicated at the top of the panelp300(D242±1737), which contains a carboxyl-terminal
were probed in a Western blot with an ascites-purified anti-p53activation domain (Yuan et al., 1996) along with the bind-
antibody, pAb421.
ing site for c-Jun (Lee et al., 1996), one of the main
components of the AP1 class of transcription factors.
original enhancer activity was restored in these assays.Transfection of the vector encoding wild-type p53 re-
To rule out the possibility that the interaction of p53sulted in a dose-dependent inhibition of the reporter
with p300 might structurally prevent other componentsactivity (data not shown), and high concentrations of
of AP1 from binding to the DNA, gel retardation experi-the p53-encoding plasmid almost completely silenced
ments were performed. As shown in Figure 6D, neitherTRE transcription (Figure 6B). Strikingly, p53 prevented
wild-type nor mutant p53 modified the total amounts ofthe activation of the reporter driven by full-length p300
the DNA-bound complexes or their composition, sincebut not by p300(D242±1737), which lacks the region re-
Jun and Fos appear to be the main components of AP1quired for the interaction with p53. These results suggest
in the presence or absence of overexpressed p53.that the association between p53 and p300 might, at
least partially, account for p53-induced inhibition of the
Effects of Dominant Negative p300 onTRE.
p53-Mediated Apoptosis and G1 ArrestOne possibility suggested by the above data is that
p53 is known to respond to multiple signals of cellularthe formation of p53-p300 complexes reduces the
damage by inducing either a transient growth arrest oramount of p300 available for transcriptional activation.
apoptosis (reviewed by Ko and Prives, 1996; Bates andIn such a case, overexpression of p300 is expected to
Vousden, 1996; Levine, 1997). Our findings have impli-overcome the inhibition. As shown in Figure 6C, trans-
cated p300 as a target of p53 and we have identified afection of the vector encoding p300 prevented p53-
p300 fragment, p300(1514±1922), that interferes with theimposed repression of the TRE reporter in a dose-
activity(s) of endogenous proteins. Thus, to establishdependent manner. On average, more than half of the
the role of p300 in p53-signaling we examined the effects
of p300(1514±1922) on cells treated with either ionizing
radiation or anticancer agents, both of which are essen-These sets of experiments were performedmultiple times in different
tial upstream modulators of p53.cell lines, and the results shown represent the average of three
independent experiments. First, the effects of p300(1514±1922) on p53-directed
Cell
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Figure 6. Inhibition of TRE-Mediated Transcription by p53 and Its
Reversion by p300
A luciferase reporter plasmid driven by the phorbolester-responsive
Figure 7. Effects of p300(1514±1922) on p53-Mediated Apoptosiselement (TRE), which contains four copies of the DNA binding se-
quences for the transcription factor AP1, was used in these assays. SAOS-2 cells were transfected with 1/20 (v/v) of a transfection reac-
(A) Effects of p53 wild-type and mutant on the TRE. Two micrograms tion containing 30 ml of lipofectamine (GIBCO±BRL) and: 21 mg of
of CMVp53Val135 encoding the temperature-sensitive p53 mutant the control, backbone plasmid CMV0 (A); 7 mg of the p53 expressing
(p53 Val135) were cotransfected in CV1 cells together with 1 mg of vector (CMVp53) and 14 mg of the CMV0 (B); 7 mg of the CMVp53
the reporter. Transfection was carried out by using lipofectamine. plasmid and 14 mg of the p300(1514±1922) (C). Twenty-four hours
Cells were incubated at 32.58C (black bars) or 39.58C (gray bars) after transfection, cells were exposed to doxorubicin (5 mg/ml) and
and luciferase levels were determined 24±36 hr later. reincubated for an additional 12 hr. Double staining for p53-expres-
(B) p53 inhibits TRE-dependent transcription and its activation by sion (rodhamine, left panels) and apoptosis (fluorescein, right pan-
full-length p300 but not by p300 molecules lacking the p53 binding els) was performed as described in the Experimental Procedures.
site, p300(D242±1737). CV1 cells were cotransfected with 1 mg of
the reporter and 2 mg of the plasmids expressing full-length p300,
or the p300(D242±1737), or the control plasmid CMV0, alone or in
combination with 2 mg CMVp53 vector, as indicated in the panel. killing of neoplastic cells in response to the anticancer
(C) Dose-dependent relief of the p53-imposed repression of the TRE drug doxorubicin were assessed. SAOS-2 cells, which
by p300. Two micrograms of the CMVp53 plasmid were cotrans- do not express endogenous p53, were transfected either
fected together with increasing concentrations (1, 2, and 4 mg, re-
with the control vector CMV0, or with the vector encod-spectively) of the p300 expressing vector as indicated at the bottom
ing p53 (CMVp53) alone or in combination with theof the panel.
p300(1514±1922). Twenty-four hours after transfection(D) The expression of wild-type p53 and of the mutant p53 Val135
does not modify the composition of the TRE-bound complexes. cells were treated with doxorubicin and apoptotic fea-
HeLa cells were mock transfected (lanes 1 to 4) or transfected with tures evaluated 12 hr later. The cells were double-
either 10 mg of the CMVp53 (lanes 5 to 7) or 10 mg of CMVp53 Val135 stained for p53 expression and for DNA breaks, char-
(lanes 8 to 10), together with 5 mg of the pHook vector (Invitrogen)
acteristic of apoptotic induction (TUNEL). The resultsencoding a cell surface antigen to select transfected cells. Cells
are shown in Figure 7, and quantified in Table 1. In thewere incubated at 378C (lanes 1 to 7) or 39.58C (lanes 8 to 9), and 48
absence of p53 expression, less than 20% of SAOShr later transfected cells were isolated by using a magnetic sorting
procedure according to the manufacturer's instruction. Nuclear cell cells treated with doxorubicin were positive for TUNEL
extracts were prepared as described in the Experimental Proce- staining (Figure 7A). Approximately 95% of cells trans-
dures. EMSAs were performed by using a labeled oligonucleotide fected with p53 alone (Figure 7B) and treated with doxo-
containing a single copy of the DNA-binding site for AP1 (Promega).
rubicin demonstrated clear apoptotic features, evalu-Extracts were incubated with the probe alone (lanes 1, 5, and 8),
ated by either the intensity of the staining or morphologywith an anti-Jun (lane 2, 6, and 9), or anti-Fos (lanes 3, 7, and 10)
of thenuclei, indicating that in this cell line and under theantibodies, respectively. Lane 4 contains the competition with a
10-fold excess of unlabeled oligonucleotide on nuclear extracts of conditions that we employed, apoptosis occurs through
mock-transfected cells. 53-dependent pathways. Coexpression of p53 and
p300/CBP-p53 Cross-Talk
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Table 2. p300 1514±1912 Perturbs IR-Induced Cell-Cycle ArrestTable 1. Inhibition of Apoptosis by the p300 (1514±1922)
Vector IR G1 (%) S (%) G2/M (%)Vector Apoptotic Cells (%)
Random phase cellsCMVO 14
CMVp53 1 CMV0 95 CMVO 2 65.4 23.5 9
CMVO 1 70.3 1.3 22.5CMVp53 1 p300 (1514±1922) 43
p300(1514±1912) 1 74.7 4.2 15.4
Fluorescein-TUNEL assay was performed as described in Figure 7, Cells treated with nocodazole
and the results were quantified by counting the cells of 14 nonadja- CMVO 2 70 11 15.7
cent fields of samples derived from a triplicate experiment. The CMVO 1 72 1.3 22.1
results express percentage values of the number of apoptotic cells. p300(1514±1912) 1 63.8 5.8 23.6
MCF7 cells were cotransfected with 15 mg of either the control
plasmid CMV0 or with p300(1514±1922) and with 7 mg of a vector
encoding the cell surface receptor for IL2 (CMV-IL2R). Nontreatedp300(1514±1922) resulted in a significant reduction of
(random phase) and nocodazole treated (15 mg/ml) cells are shown.the cells in late or early apoptotic stages (Figure 7C).
Nocodazole was added 4 hr after IR. Cells were harvested 24 hrThe percentage of apoptotic cells in the presence of
after IR, and they were labeled during the final 30 min of culture withthe p300(1514±1922) was approximately 43%, twice the
BrdUrd. Magnetic affinity cell sorting was performed as described
levels seen in the p53 (2) background, and about half in the Experimental Procedures. For flow cytometry, nuclei from
the levels obtained by expression of the p53 alone (Table transfected cells were fixed with ethanol and stained with FITC-
conjugated anti-BrdUrd (Becton-Dickinson) and propidium iodide1), thus indicating that p300(1514±1922) induces a signif-
according to the manufacturer's protocol. Stained nuclei were ana-icant inhibition of p53-mediated apoptosis.
lyzed on FACScan (Becton-Dickinson) using LysisII software. TheIn a further set of experiments, we investigated
number of cells in each sample analyzed was approximately 5 3whether p300(1514±1922) could perturb p53-mediated
103. The experiments were performed4 times and 2 times for random
G1 arrest following IR. The human breast carcinoma phase or nocodazole-treated cells, respectively, with results similar
cell line MCF7 was utilized because it responds to IR to those shown.
treatment with cell-cycle arrest at the G1 and G2 check-
points in a p53-dependent manner (Fan et al., 1995).
The vector encoding p300(D1514±1922) or the control complexes bound to DNA containing p53-binding con-
sensus sites (Figures 1 and 2). Remarkably, p53-p300vector CMV0 were transfected into MCF7 cells together
with a plasmid encoding the IL2 receptor, which served complexes were detected in a variety of cell lines, includ-
ing human, rat, and mouse cells, thus indicating thatas a selection marker to isolate transfected cells (Gior-
dano et al., 1991). Sixteen to 18 hr after irradiation, cells this interaction is conserved among different species.
Previous reports have shown that complexes betweenwere processed for cell cycle analysis. The effect of
p300(1514±1922) was examined first in random-phase p300/CBP, p53 and theviral protein SV40 large T antigen
(Tag) are detected in cells constitutively expressing theexponentially growing cell cultures. Treatment of control
cells with IR induced cell cycle arrest in G1 and G2 and early products of SV40 virus (Eckner et al., 1996b; Lill
et al., 1997). In keeping with this observation and givena significant reduction in the cells progressing through
S phase (Table 2). This is consistent with p53 acting at the well-known cell cycle and cell-growth regulatory ac-
tivity of SV40 Tag, it seems likely that p53-p300 com-the G1/S and G2/M checkpoints (Ko and Prives, 1996;
and references therein). Expression of p300(1514±1922) plexes might operate in diverse aspectsof cellular prolif-
eration. Results presented in this study are consistentpartially inhibited the radiation-induced G2 arrest and
increased the percentage of the cells inS phase. Despite with this view. p53 has a well-documented activity as a
transcriptional activator, which is clearly required for itsan increase in the percentage of cells in S phase, which
aredrawn from thepool of thecells in G1, thepercentage cell-cycle arrest function. As shown in Figures 4 and 5,
p300 acts cooperatively with wild-type p53 to stimulateof cells in G1 also was found to be increased, likely as
a consequence of the cells released from the G2/M transcription from a p53-dependent promoter. A small
p300 fragment (p300 1514±1922) containing the regionblock. To evaluate more clearly the effects of p300 on
G1/S transition, similar experiments were next per- required for the interaction with p53 prevents the activa-
tion of a p53-regulated promoter, implying that p300 isformed in a cell population treated with nocodazole to
inhibit transit from G2 to M. In the presence of nocoda- an important component of p53-directed transcription.
Strikingly, p300 expression significantly increases thezole, p300(1514±1922) reduced the fraction of the cells
in G1 below that of nonirradiated cells and again in- responsiveness to a physiological upstream regulator
of the action of p53, such as ionizing radiation. Consis-creased the fraction of cells in S phase. The data thus
support the conclusion that the p300(1514±1922) inhib- tent with its ability to interfere with the activity of endog-
enous p300, p300(1514±1922) inhibited irradiation-its p53-dependent signal pathways through dominant
negative activity(s) for endogenous p300. induced G1 arrest. For p53, as it is true with a variety
of transcription factors, p300 plays a stimulatory role in
transactivation. Therefore, in the context of p53-medi-Discussion
ated growth suppression, p300 can beviewed as a nega-
tive regulator of cell growth.The results of this study establish a fundamental role
for p300 in the biological activities of p53. The physical The activation of severalpromoter/enhancer elements
that also function in a p300-dependent manner, suchassociation of p53 and p300 was determined by their
coprecipitation as soluble complexes or by the ability as the AP1 and c-Fos promoters (Arias et al., 1994), has
been correlated to promotion of G1±S transition, cellularof an antibody directed against p300 to supershift p53
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proliferation, and/or transformation (reviewed by Angel apoptosis. Moreover, although the evidence implicating
and Karin, 1991). Thus, while recruiting p300 on certain p300 as an integrator of transcriptional responses is
promoters, p53 could also inhibit selected transactivat- overwhelming, it is likely that p300-activities other than
ing functions of p300 on others. In this study, we have transcriptional regulation do exist, as indicated by the
shown that wild-type p53 inhibits p300-mediated activa- ability of this protein to associate with cell-cycle regu-
tion of a promoter containing the DNA-binding sites for lated cyclins and kinases (Yaciuk and Moran, 1991; Per-
the transcription factor AP1 (TRE) (Figure 6). This effect kins et. al., 1996; Janknecht and Hunter, 1996b, and
is at least partially dependent on the formation of p53- references therein). Thus, the establishment of p300 as
p300 complexes since p53 failed to prevent the stimula- an effector of p53-dependent pathways then suggests
tory effect of a p300 fragment missing the region re- an important point of potential cross-talk between p53
quired for the association. The identification of p300 as and different classes of regulatory proteins in the cell,
an important component of p53-mediated transcription, an especially relevant consideration given the complex-
together with the notion that the concentration of p300 ity of the downstream events mediated by p53. Because
is rate limiting in the cells (Kamei et al., 1996), suggests p300 is a multifunctional molecule, it will be very infor-
a mechanism by which p53 might inhibit AP1 activation mative to correlate its mutations (either naturally oc-
based on the requirement for p300 by both classes of curring or engineered) with phenotypic readouts. The
transcription factors. The observation that increased role of p300 in p53-dependent pathways alerts one to
levels of p300 overcome p53-mediated inhibition of the the possibility that mutations of the p300 gene may be
TRE strongly supports this interpretation (Figure 6). Non- selected to downregulate or eliminate p53 activity(s) in
mutually-exclusive explanations, however, include post- certain situations such as oncogenesis.
translational modifications of the proteins and/or
change in the composition of the complexes that might
Experimental Procedures
act to redirect p300 activities from AP1 to p53-regulated
promoters. In this regard, it is intriguing that p53 binds to Cells, Plasmids, and Antibodies
p300 in a region that is required for the intrinsic histone Monolayers of African green monkey kidney cells, CV1, 293, REF52,
SAOS-2, and MEF (p532/2) cells were grown in Dulbecco's modifiedacetyl transferase activity (Ogryzko et al., 1996), but it
Eagle's medium (DMEM) supplemented with 10% fetal calf serumis distinct from the binding domain for c-Jun (Lee et al.,
(FCS). The anti-p300 polyclonal antiserum has been described else-1996), P/CAF (Yang et al., 1996) and TBP (Yuan et al.,
where (Avantaggiati et al., 1996). The anti-p300 and anti-CBP mono-1996), all of which are presumably important modulators
clonal antibodies were purchased from UBI. The anti-p53 specific
of the activity of this protein oncertain promoters. There- antibody, pAb421, employed for immunoprecipitation, is an IgG2A
fore, p53 might function directly, i.e., through protein± mouse monoclonal antibody purchased from Oncogene Science.
protein interactions, by sequestering p300 itself and per- The pAb421 used in the gel retardation assays is an ascities-purified
antibody provided by T. Melendy. The CMV-p300 plasmid was pro-haps other p300-associated factors. As shown here for
vided by R. Eckner and D. Livingston; the CMVp53 Val135 was athe p53 Val135 mutation (Figure 6) and elsewhere for
gift from M. Oren.others, mutated forms of p53 lose the transcriptional
repression activity, thus emphasizing the importance of
Transfections and Reporter Assaysthis function for the integrity of p53-dependent path-
Transfections were performed by using either lipofectamineways. The finding that p53 Val135 is capable of inter-
(GIBCO±BRL) or a calcium phosphate-based method (Pharmacia).
acting with p300 (Figure 2), although to a lesser extent, Early-passage cell cultures were employed for both reporter assays
might indicate that the inhibition of AP1-directed tran- and immunoprecipitation experiments. For transactivation assays,
scription requires a native conformation for the interac- cells were plated at 20%±40% confluence 12±18 hr prior to transfec-
tion. All expressing vectors employed in this study were driven bytion with proteins other than p300 (which may them-
the CMV promoter. Unless otherwise indicated, transfections wereselves be associated with p300) yet is important for
carried out by using a ratio between reporter and activators of 1:2.transcriptional regulation.
Usually, 0.5±1 mg of reporter plasmid and 1±2 mg of activator wereWhat role does p300 play in p53-directed killing of
transfected in the combinations indicated in the figure legends.
the cells? Our results imply that the activity(s) of p300 When necessary the total content of transfected DNA was equalized
is required for this effect, since a dominant negative form with either the control backbone plasmid, CMV0, or with pUC19.
of this protein partially rescued doxorubicin-mediated Cells were exposed to lipofectamine or to calcium phosphate for
about 12 hr, washed twice with PBS, and reefed with completeapoptosis. Recent investigations have shown that the
medium. Equal amounts of cell lysates were employed for detectionexpression of viral or cellular oncogenes, bcl-2 and E1B-
of luciferase activity (Promega).19K for example, reverses p53-mediated inhibition of
endogenous genes and inhibits apoptosis (Shen and
Immunoprecipitations and Western BlotShenk, 1994; Murphy et al., 1996). Moreover, certain p53
One to 3 mg of total cell extracts was prepared from either
deletion mutants that lack the transactivating function transfected or untransfected cells by incubating the cells in buffer
induce apoptosis in several cell lines but not in others A (20 mM NaPO4 [pH 7.8], 240 mM NaCl, 0.1% NP40, 5 mM EDTA,
(Haupt et al., 1995). Thus, in addition to transactivation- 1 mM DTT) supplemented with freshly prepared protease and phos-
dependent modes of apoptosis, p53 might use alterna- phatase inhibitors (10 mM sodium fluoride, 1 mM sodium orthovana-
date, 1 mM phenylmethylsulfonylfluoride, and leupeptin, aprotinin,tive pathways, such as the downregulation of genes
and pepstatin at 10 mg/ml each). After incubation (109, 48C), extractscritical for survival or direct signaling through protein±
were centrifuged at 12,000 rpm, and the supernatants were col-protein interactions (reviewed by Levine, 1997). Data
lected. Pellets were resuspended in 2 vol of buffer A, vortexed, and
presented here have implicated p300 inboth the transre- incubated on ice for an additional 10 min. Extracts from these two
pressing and transactivating activity of p53 suggesting extractions were combined and precleared twice with an excess of
that the imbalance of p300 activity(s) at targetedpromot- Protein A. Typically, 1/5 of the total extract was immunoprecipitated
with the anti-p300 antiserum and the remaining with the anti-p53ers might play a role in the execution of p53-mediated
p300/CBP-p53 Cross-Talk
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antibody. The volumes of the reactions were below 1 ml, and the confocal microscopy. The authors thank Dr. Bruce Howard and Dr.
Albert J. Fornace for access to the FACScan and to the gamma-antibodies dilutions were 1:100 for the anti-p300 antiserum and
1/10 (v/v) for the pAb421. Immunoprecipitations were carried out at irradiator, respectively. Dr. Ettore Appella, Dr. Richard Eckner, Dr.
David Livingston, and Dr. Moshe Oren are acknowledged for provid-48C for 45±90 min, precipitates were washed 3±6 times in lysis buffer,
eluted in 23 SDS sample buffer, loaded on 7.5% SDS±PAGE gels ing several vectors employed in this study. The authors thank Dr.
Victor J. Hernandez, Dr. Massimo Levrero, Dr. Yoshihiro Nakatani,(30:0.7 Acryl/Bis), and run overnight. After transfer at 65 V for 4.5
hr at room temperature, membranes were incubated in blocking Dr. Edward G. Niles, Dr. Thomas Melendy, and Dr. Lorenzo Puri
for helpful discussions and criticism during the preparation of thesolution (10% Horse Serum, 0.1% Tween 20, in 13 PBS) for 6 hr and
overnight with anti-p300 antibody (UBI). Immunocomplexes were manuscript.
detected by using a chemiluminescence-based system (Amersham)
according to the manufacturer's instructions. Received May 7, 1997; revised June 13, 1997.
Gel Retardation Assays
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